Summary List Placement
Today in healthcare news: EQRx has raised another $500 million, at least 50% of COVID-19 cases spread from people without symptoms, and some evidence that Pfizer’s vaccine works against virus mutations.
- EQRx, a company developing new drugs that’ll compete with some of the highest-priced drugs on the market at a lower price, is moving faster than it expected.
- A year in, the startup just raised a fresh $500 million from investors including GV, Andreessen Horowitz, and Arch Venture Partners, as well as from private equity funds, health plans and health systems.
- It aims to get have its first treatment approved in the next “handful of years” and has brought on four cancer drugs that are in later stages of development.
- At least 50% of new COVID-19 cases are transmitted by people who don’t show symptoms, according to a new study.
- That includes people who never display symptoms and those whose symptoms hadn’t started yet.
- A study authors said findings underscore the need for people who feel healthy to follow public-health guidance on mask wearing and social distancing.
- A study by Pfizer and researchers at the University of Texas Medical Branch indicates the company’s COVID-19 vaccine is effective against mutations of the coronavirus.
- The study has not yet been peer-reviewed.
- “So we’ve now tested 16 different mutations, and none of them have really had any significant impact. That’s the good news,” Phil Dormitzer, a scientist at Pfizer, said Thursday. “That doesn’t mean that the 17th won’t,” he added.
More stories we’re reading:
- How West Virginia is winning the race to get COVID-19 vaccines into people’s arms, including using its own pharmacies (NPR)
- Biden plans to release the entire coronavirus vaccine supply instead of reserving half to guarantee second doses (Business Insider)
- LA is facing its “New York Moment” as the virus overwhelms the largest county in the US (The New York Times)
- I felt totally fine after my first COVID-19 shot, but the second dose was rough. Here’s what I did to manage the side effects and why I still think you should get the shot. (Business Insider)